首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1341912

全球糖尿病治療和診斷市場

Global Markets for Diabetes Therapeutics and Diagnostics

出版日期: 2023年08月31日 | 出版商:

BCC Research | 英文 336 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球糖尿病治療和診斷市場預計將從2023年的1022億美元成長到2028年的1320億美元，預測期內年複合成長率為5.2%。

治療行業預計將從 2023 年的 593 億美元成長到 2028 年的 722 億美元，年複合成長率為 4.0%。與此同時，糖尿病監測設備和配件領域預計將從 2023 年的 250 億美元成長至 2028 年的 341 億美元，年複合成長率為 6.4%。

本報告調查了全球糖尿病治療和診斷市場，並提供了市場概況、市場影響因素和市場機會分析、技術發展趨勢、產品平臺、市場規模趨勢和預測，以及各個細分市場和地區的細分。詳細分析、ESG發展歷程、競爭形勢、主要企業概況等

概述
胰島素注射器
使用胰島素注射器的好處
使用胰島素注射器的缺點
胰島素注射器的最新技術進步和發展
胰島素注射筆裝置
拋棄式胰島素筆
可重複使用的胰島素筆
胰島素劑量筆設備的最新技術進步和發展
胰島素噴射注射器
使用胰島素噴射注射器的好處
使用胰島素噴射注射器的缺點
外部胰島素泵
胰島素泵的好處
胰島素泵的缺點
胰島素泵系統的最新技術進步和發展
植入式胰島素泵
閉迴路人工胰腺
仿生胰腺
人工胰腺（生理方法）
胰島素吸入器
胰島素吸入器的好處
胰島素吸入器的缺點
胰島素吸入器的類型
胰島素貼片
口服胰島素給藥

第7章全球糖尿病治療和診斷市場（按最終用戶）

概述
醫院/診所
診斷中心
家庭護理組織

第8章全球糖尿病治療和診斷市場（按地區）

概述
北美
美國
加拿大
歐洲
德國
英國
法國
西班牙
義大利
歐洲其他地區
亞太地區
中國
印度
日本
澳大利亞
亞太地區其他地區
其他地區
南美洲
中東/非洲

第9章糖尿病治療和診斷市場的永續性：ESG 視角

ESG績效分析

第10章新興技術

超出血糖控制範圍的患者治療結果
利用數位健康的糖尿病技術
口服抗糖尿病藥物的成長趨勢
更加關注醫療保健的可及性和可負擔性
人工胰腺

第11章併購與風險投資預測資金籌措

併購分析
禮來公司收購Protomer Technologies

第12章競爭形勢

主要企業近期的戰略舉措

第13章公司簡介

77 ELEKTRONIKA KFT.
ABBOTT
ALTUCELL
ASCENSIA DIABETES CARE HOLDINGS AG.
ASTRAZENECA
B. BRAUN SE
BIOCON
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DANAHER
DEXCOM INC.
EMBECTA CORP.
INSULET CORPORATION.
JOHNSON & JOHNSON SERVICES INC.
LIFESCAN IP HOLDINGS LLC
LILLY
MEDTRONIC
MENARINI GROUP (A. MENARINI DIAGNOSTICS SRL)
MERCK & CO. INC.
MERCK KGAA
NEXTCELL PHARMA AB
NIPRO
NOVA BIOMEDICAL
NOVARTIS AG
NOVO NORDISK A/S
ROCHE (F. HOFFMANN-LA ROCHE LTD)
SANOFI
TAKEDA PHARMACEUTICAL COMPANY LIMITED.
TANDEM DIABETES CARE INC.
TERUMO CORPORATION
YPSOMED AG

第14章附錄

政府法規機構和專業組織

簡介目錄圖表

Product Code: HLC029F

Highlights:

The global market for diabetes therapeutics and diagnostics is estimated to increase from $102.2 billion in 2023 to reach $132.0 billion by 2028, at a compound annual growth rate (CAGR) of 5.2% from 2023 through 2028.

The global market for diabetes therapeutics is estimated to increase from $59.3 billion in 2023 to reach $72.2 billion by 2028, at a compound annual growth rate (CAGR) of 4.0% from 2023 through 2028.

The global market for diabetes monitoring devices and accessories is estimated to increase from $25.0 billion in 2023 to reach $34.1 billion by 2028, at a compound annual growth rate (CAGR) of 6.4% from 2023 through 2028.

Report Scope:

This report discusses the implications of the trends mentioned above in the context of the current size and growth of the diabetes market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug and device categories, and there are country-level breakdowns of the diabetes market.

Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the diabetes therapeutics and diagnostics market.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data is provided for 2022 as the base year, 2023 and forecast through year-end 2028.

Report Includes:

162 data tables and 63 additional tables
An up-to-date overview and analysis of the global markets for diabetes therapeutics and diagnostics
Analyses of the global market trends, with market revenue (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Understanding of the upcoming market potential for AI in diabetic mellitus management with an emphasis on new products and solutions/platform technologies, and areas of focus to forecast this market into various segments and sub-segments
Estimation of the actual market size and revenue forecast for the global diabetes therapeutics and diagnostics market, and corresponding market share analysis based on product type, end user, and geographical region
In-depth information (facts and figures) on major market dynamics, opportunities and gaps estimating the demand, technology adaptations in diabetes care, industry developments, regulatory dynamics, and the COVID-19 impact on the progress of this market
Identification of the companies best positioned to meet this demand owing to or in conjunction with their proprietary technologies, product launches, and other strategic advantages
Review of key patent grants and patent applications on diabetes therapeutics and diagnostics, and emerging technologies and new developments in this market
Analysis of the company competitive landscape based on their recent developments, financial performance, segmental revenues, and operational integration
Company profiles of the leading global players, including Novo Nordisk, Sanofi S.A., Lilly, Takeda, Danaher Corp., and AstraZeneca

Chapter 1 Introduction

Diabetes
Type 1 Diabetes
Type 2 Diabetes
Study Goals and Objectives
Reasons for Doing This Study
What's New in This Report
Scope of Report
Information Sources
Methodology
Secondary Research
Primary Interviews
Geographic Breakdown

Chapter 2 Summary and Highlights

Market Overview
Significant Developments and Trends

Chapter 3 Market Overview

What is Diabetes?
Types of Diabetes
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes Mellitus (GDM) or Hyperglycemia in Pregnancy
Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG)
Epidemiology of Diabetes
Gender Distribution
Regional Disparities
Market Factors Driving the Growth and Development of the Market
Market Drivers
Market Restraints

Chapter 4 Global Market for Diabetes Therapeutics

Overview
Classification and Types of Antidiabetic Medications
Injectable Therapies for Diabetes
Oral Antidiabetic Drugs (OADs)
Facing the Patent Cliff
Latest Technological Advances, Developments and Product Pipelines for Diabetic Medications
Current Product Pipeline
Other Potential Therapies Currently Under Investigation

Chapter 5 Global Market for Diabetes Monitoring Devices and Accessories

Overview
Self-Monitoring of Blood Glucose (SMBG)
SMBG Market Structure
Latest Technological Advances and Developments in Blood Glucose Devices
Continuous Glucose Monitoring (CGM) Systems
Development of CGM Systems

Chapter 6 Global Market for Diabetes Delivery Devices by Type

Overview
Insulin Syringes
Advantages of Using Insulin Syringes
Disadvantages of Using Insulin Syringes
Latest Technological Advances and Developments in Insulin Syringes
Insulin Delivery Pen Devices
Disposable Insulin Pens
Reusable Insulin Pens
Latest Technological Advances and Developments in Insulin Delivery Pen Devices
Insulin Jet Injectors
Advantages of Using Insulin Jet Injectors
Disadvantages of Using Insulin Jet Injectors
External Insulin Pumps
Advantages of Insulin Pumps
Disadvantages of Insulin Pumps
Latest Technological Advances and Developments in Insulin Pump Systems
Implantable Insulin Pumps
Closed-Loop Artificial Pancreas
Bionic Pancreas
Artificial Pancreas (the Physiological Approach)
Insulin Inhalers
Advantages of Insulin Inhalers
Disadvantages of Insulin Inhalers
Types of Insulin Inhalers
Insulin Patches
Oral Insulin Delivery

Chapter 7 Global Market for Diabetes Therapeutics and Diagnostics by End User

Overview
Hospitals and Clinics
Diagnostic Centers
Home Care Organizations

Chapter 8 Global Market for Diabetes Therapeutics and Diagnostics by Region

Overview
North America
United States
Canada
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
Rest of the World
South America
Middle East and Africa

Chapter 9 Sustainability in the Market for Diabetes Therapeutics and Diagnostics: An ESG Perspective

Introduction
Market for Diabetes Therapeutics and Diagnostics: ESG Performance Analysis

Chapter 10 Emerging Technologies

Patient Outcomes Beyond Glucose Control
Diabetes Technology with Digital Health
Growing Trend Toward Oral Antidiabetics
Growing Focus on Accessibility and Affordability of Medicine
Artificial Pancreas

Chapter 11 M&As and Venture Funding Outlook in the Market

M&A Analysis
Lilly's Acquisition of Protomer Technologies

Chapter 12 Competitive Landscape

Recent Strategic Initiatives, By Major Players in The Market

Chapter 13 Company Profiles

77 ELEKTRONIKA KFT.
ABBOTT
ALTUCELL
ASCENSIA DIABETES CARE HOLDINGS AG.
ASTRAZENECA
B. BRAUN SE
BIOCON
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DANAHER
DEXCOM INC.
EMBECTA CORP.
INSULET CORPORATION.
JOHNSON & JOHNSON SERVICES INC.
LIFESCAN IP HOLDINGS LLC
LILLY
MEDTRONIC
MENARINI GROUP (A. MENARINI DIAGNOSTICS S.R.L)
MERCK & CO. INC.
MERCK KGAA
NEXTCELL PHARMA AB
NIPRO
NOVA BIOMEDICAL
NOVARTIS AG
NOVO NORDISK A/S
ROCHE (F. HOFFMANN-LA ROCHE LTD)
SANOFI
TAKEDA PHARMACEUTICAL COMPANY LIMITED.
TANDEM DIABETES CARE INC.
TERUMO CORPORATION
YPSOMED AG

Chapter 14 Appendix

Government Regulatory Agencies and Professional Organizations

簡介目錄圖表

List of Tables

Summary Table : Global Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 1 : Key Facts and Latest Data for Diabetes Globally, 2021 and 2045
Table 2 : Global Diabetes Estimates and Projections, 2019-2045
Table 3 : Global Prevalence of Diabetes, by Type, Through 2040
Table 4 : Global Diabetes Cases, by Country, 2000-2045
Table 5 : Age-Adjusted Comparative Prevalence of Diabetes, by Region, 2010-2040
Table 6 : First-Time Generic Drug Approvals for Type 2 Diabetes, October 2022-2021
Table 7 : Global Revenues of Leading Antidiabetic Pharmaceutical Companies, 2022
Table 8 : Comparison of Insulin Action of Leading Insulin Products
Table 9 : Comparison of GLP-1 Analogs
Table 10 : U.S. Patent Expiry Dates for the World's Top Selling Diabetes Drugs
Table 11 : Novo Nordisk's Current R&D Pipeline
Table 12 : Lilly's Current R&D Pipeline
Table 13 : AstraZeneca's Current R&D Pipeline
Table 14 : Terminology Used to Describe Generic Biopharmaceuticals, by Country/Region
Table 15 : Global Market for Diabetes Therapeutics, by Region, Through 2028
Table 16 : Global Market for Diabetes Therapeutics, by Type, Through 2028
Table 17 : Global Market for Injectable Diabetes Therapies, by Region, Through 2028
Table 18 : Global Market for Oral Antidiabetic Drugs, by Region, Through 2028
Table 19 : Global Market for Injectable Diabetes Therapies, by Type, Through 2028
Table 20 : Global Market for Diabetic GLP-1 Therapy, by Region, Through 2028
Table 21 : Global Market for Insulin Therapy, by Region, Through 2028
Table 22 : Leading Blood Glucose Manufacturers and Blood Glucose Products
Table 23 : Leading Lancet and Lancet Device Manufacturers and Products
Table 24 : Comparison of Abbott Freestyle Blood Glucose Monitoring System Readers
Table 25 : Global Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 26 : Global Market for Diabetes Monitoring Devices and Accessories, by Region, Through 2028
Table 27 : Global Market for Blood Glucose Test Strips, by Region, Through 2028
Table 28 : Globa Market for Blood Glucose Meters, by Region, Through 2028
Table 29 : Global Market for Lancets and Lancet Devices, by Region, Through 2028
Table 30 : Global Market for Continuous Glucose Monitoring Systems, by Region, Through 2028
Table 31 : Leading Insulin Syringes Manufacturers and Insulin Syringe Products
Table 32 : Commercially Available Insulin Injector Pens
Table 33 : Leading Insulin Jet Injectors Manufacturers and Products
Table 34 : Leading External Insulin Pump Manufacturers and Products
Table 35 : Key Features of Current Leading Insulin Pump Systems
Table 36 : Global Market for Diabetes Delivery Devices, by Type, Through 2028
Table 37 : Global Market for Diabetes Delivery Devices, by Region, Through 2028
Table 38 : Global Market for Insulin Syringes, by Region, Through 2028
Table 39 : Global Market for Insulin Pens and Needles (Reusable and Disposable), by Region, Through 2028
Table 40 : Global Market for Insulin Jet Injectors, by Region, Through 2028
Table 41 : Global Market for External Insulin Pumps, by Region, Through 2028
Table 42 : Global Market for Implantable Insulin Pumps, by Region, Through 2028
Table 43 : Global Market for Insulin Inhalers, by Region, Through 2028
Table 44 : Global Market for Insulin Patches, by Region, Through 2028
Table 45 : Global Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 46 : Global Market for Diabetes Therapeutic and Diagnostics in Hospitals and Clinics, by Region, Through 2028
Table 47 : Global Market for Diabetes Therapeutic and Diagnostics in Diagnostic Centers, by Region, Through 2028
Table 48 : Global Market for Diabetes Therapeutics and Diagnostics in Home Care Organizations, by Region, Through 2028
Table 49 : Global Market for Diabetes Therapeutics and Diagnostics, by Region, Through 2028
Table 50 : North American Market for Diabetes Therapeutics and Diagnostics, by Country, Through 2028
Table 51 : North American Market for Diabetes Therapeutics and Diagnostics, by Segment Type, Through 2028
Table 52 : North American Market for Diabetes Therapeutics, by Type, Through 2028
Table 53 : North American Market for Injectable Therapies, by Type, Through 2028
Table 54 : North American Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 55 : North American Market for Diabetes Delivery Devices, by Type, Through 2028
Table 56 : North American Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 57 : U.S. Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 58 : U.S. Market for Diabetes Therapeutics, by Type, Through 2028
Table 59 : U.S. Market for Injectable Therapeutics, by Type, Through 2028
Table 60 : U.S. Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 61 : U.S. Market for Diabetes Delivery Devices, by Type, Through 2028
Table 62 : U.S. Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 63 : Canadian Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 64 : Canadian Market for Diabetes Therapeutics, by Type, Through 2028
Table 65 : Canadian Market for Injectable Therapeutics, by Type, Through 2028
Table 66 : Canadian Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 67 : Canadian Market for Diabetes Delivery Devices, by Type, Through 2028
Table 68 : Canadian Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 69 : European Market for Diabetes Therapeutics and Diagnostics, by Country, Through 2028
Table 70 : European Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 71 : European Market for Diabetes Therapeutics, by Type, Through 2028
Table 72 : European Market for Injectable Therapeutics, by Type, Through 2028
Table 73 : European Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 74 : European Market for Diabetes Delivery Devices, by Type, Through 2028
Table 75 : European Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 76 : German Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 77 : German Market for Diabetes Therapeutics, by Type, Through 2028
Table 78 : German Market for Injectable Therapeutics, by Type, Through 2028
Table 79 : German Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 80 : German Market for Diabetes Delivery Devices, by Type, Through 2028
Table 81 : German Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 82 : U.K. Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 83 : U.K. Market for Diabetes Therapeutics, by Type, Through 2028
Table 84 : U.K. Market for Injectable Therapeutics, by Type, Through 2028
Table 85 : U.K. Market for Diabetes Monitoring Device and Accessories, by Type, Through 2028
Table 86 : U.K. Market for Diabetes Delivery Devices, by Type, Through 2028
Table 87 : UK Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 88 : French Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 89 : French Market for Diabetes Therapeutics, by Type, Through 2028
Table 90 : French Market for Injectable Therapeutics, by Type, Through 2028
Table 91 : French Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 92 : French Market for Diabetes Delivery Devices, by Type, Through 2028
Table 93 : French Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 94 : Spanish Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 95 : Spanish Market for Diabetes Therapeutics, by Type, Through 2028
Table 96 : Spanish Market for Injectable Therapeutics, by Type, Through 2028
Table 97 : Spanish Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 98 : Spanish Market for Diabetes Delivery Devices, by Type, Through 2028
Table 99 : Spanish Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 100 : Italian Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 101 : Italian Market for Diabetes Therapeutics, by Type, Through 2028
Table 102 : Italian Market for Injectable Therapeutics, by Type, Through 2028
Table 103 : Italian Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 104 : Italian Market for Diabetes Delivery Devices, by Type, Through 2028
Table 105 : Italian Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 106 : Rest of European Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 107 : Rest of European Market for Diabetes Therapeutics, by Type, Through 2028
Table 108 : Rest of European Market for Injectable Therapeutics, by Type, Through 2028
Table 109 : Rest of European Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 110 : Rest of European Market for Diabetes Delivery Devices, by Type, Through 2028
Table 111 : Rest of European Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 112 : Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by Country, Through 2028
Table 113 : Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 114 : Asia-Pacific Market for Diabetes Therapeutics, by Type, Through 2028
Table 115 : Asia-Pacific Market for Injectable Therapeutics, by Type, Through 2028
Table 116 : Asia-Pacific Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 117 : Asia-Pacific Market for Diabetes Delivery Devices, by Type, Through 2028
Table 118 : Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 119 : Major Chinese Pharmaceutical Companies Developing Antidiabetic Medicines, by Type
Table 120 : Chinese Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 121 : Chinese Market for Diabetes Therapeutics, by Type, Through 2028
Table 122 : Chinese Market for Injectable Therapeutics, by Type, Through 2028
Table 123 : Chinese Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 124 : Chinese Market for Diabetes Delivery Devices, by Type, Through 2028
Table 125 : Chinese Market for Diabetes Therapeutics and Diagnostics, by End User,
Table 126 : Indian Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 127 : Indian Market for Diabetes Therapeutics, by Type, Through 2028
Table 128 : Indian Market for Injectable Therapeutics, by Type, Through 2028
Table 129 : Indian Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 130 : Indian Market for Diabetes Delivery Devices, by Type, Through 2028
Table 131 : Indian Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 132 : Japanese Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 133 : Japanese Market for Diabetes Therapeutics, by Type, Through 2028
Table 134 : Japanese Market for Injectable Therapeutics, by Type, Through 2028
Table 135 : Japanese Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 136 : Japanese Market for Diabetes Delivery Devices, by Type, Through 2028
Table 137 : Japanese Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 138 : Australian Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 139 : Australian Market for Diabetes Therapeutics, by Type, Through 2028
Table 140 : Australian Market for Injectable Therapeutics, by Type, Through 2028
Table 141 : Australian Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 142 : Australian Market for Diabetes Delivery Devices, by Type, Through 2028
Table 143 : Australian Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 144 : Rest of Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 145 : Rest of Asia-Pacific Market for Diabetes Therapeutics, by Type, Through 2028
Table 146 : Rest of Asia-Pacific Market for Injectable Therapeutics, by Type, Through 2028
Table 147 : Rest of Asia-Pacific Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 148 : Rest of Asia-Pacific Market for Diabetes Delivery Devices, by Region, Through 2028
Table 149 : Rest of Asia-Pacific Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 150 : Rest of the World Market for Diabetes Therapeutics and Diagnostics, by Segment, Through 2028
Table 151 : Rest of the World Market for Diabetes Therapeutics, by Type, Through 2028
Table 152 : Rest of the World Market for Injectable Therapeutics, by Type, Through 2028
Table 153 : Rest of the World Market for Diabetes Monitoring Devices and Accessories, by Type, Through 2028
Table 154 : Rest of the World Market for Diabetes Delivery Devices, by Type, Through 2028
Table 155 : Rest of the World Market for Diabetes Therapeutics and Diagnostics, by End User, Through 2028
Table 156 : ESG Performance Analysis of the Market for Diabetes Therapeutics and Diagnostics
Table 157 : Social Performance of the Market for Diabetes Therapeutics and Diagnostics
Table 158 : Governance Performance of the Market for Diabetes Therapeutics and Diagnostics
Table 159 : Selected Artificial Pancreas in Clinical Trials, as of 2023
Table 160 : Mergers and Acquisitions in the Global Market for Diabetes Therapeutics and Diagnostics, January 2018 to June 2023
Table 161 : Top 10 Deals in the Market for Diabetes Therapeutics and Diagnostics, by Size, January 2018 to June 2023
Table 162 : Top 10 Deals in the Market for Diabetes Therapeutics and Diagnostics, by Status, January 2018 to June 2023
Table 163 : Global Market Share Analysis for Diabetes Therapeutics and Diagnostics, 2022
Table 164 : Global Market Share Analysis for Diabetes Therapeutics, 2022
Table 165 : Global Market Share Analysis for Diabetes Monitoring Devices and Accessories, 2022
Table 166 : Global Market Share Analysis for Diabetes Delivery Devices, 2022
Table 167 : Global Diabetes Diagnostics and Delivery Devices Market: Key Product Portfolio
Table 168 : Abbott: Financials, 2016-2022
Table 169 : Abbott: Product Portfolio, by Business Segment
Table 170 : Abbott: Recent Developments, 2023
Table 171 : AstraZeneca: Product Portfolio for Type 2 Diabetes Treatment
Table 172 : AstraZeneca: Financial Performance, 2018-2022
Table 173 : AstraZeneca: Selected Key Developments, 2023
Table 174 : Braun: Products
Table 175 : Braun: Financials, 2021
Table 176 : Biocon: Product Portfolio for Type 2 Diabetes Treatment
Table 177 : Biocon: Selected Key Developments, 2022
Table 178 : Boehringer Ingelheim: Products Portfolio for Type 2 Diabetes Treatment
Table 179 : Boehringer Ingelheim: Selected Key Developments, 2023
Table 180 : Danaher Corp.: Product Portfolio
Table 181 : Danaher Corp.: Financials, 2021
Table 182 : Danaher Corp.: Products and Services
Table 183 : Danaher Corp.: Recent Developments, 2023
Table 184 : Dexcom: Financials, 2021 and 2022
Table 185 : Insulet Corp.: Revenue, by Segment, 2020-2022
Table 186 : Johnson & Johnson: Product Portfolio for Type 2 Diabetes Treatment
Table 187 : Johnson & Johnson: Financials, 2021
Table 188 : Johnson & Johnson: Product Portfolio
Table 189 : Johnson & Johnson: Recent Developments and Strategies, 2017-2022
Table 190 : Lilly: Product Portfolio for Type 2 Diabetes Treatment
Table 191 : Lilly: Business Segments
Table 192 : Lilly: Financial Performance, 2018-2021
Table 193 : Lilly: Key Developments, 2023
Table 194 : Medtronic: Financials, 2016-2022
Table 195 : Medtronic: Product Portfolio
Table 196 : Medtronic: Patient Monitoring Device Product Portfolio
Table 197 : Medtronic: Recent Developments, 2015-2022
Table 198 : Menarini Group: Key Financials, 2021
Table 199 : Merck & Co. Inc.: Product Portfolio for Type 2 Diabetes Treatment
Table 200 : Merck & Co. Inc.: Financial Performance, 2018-2022
Table 201 : Merck KGaA: Key Financials, 2021
Table 202 : Nipro Group: Financials, 2021
Table 203 : Nipro Group: Product Portfolio, by Business Segment
Table 204 : Nipro: Recent Developments, 2020
Table 205 : Novartis: Product Portfolio for Type 2 Diabetes Treatment
Table 206 : Novartis: Key Financials, 2021
Table 207 : Novartis Key Developments, 2022
Table 208 : Novo Nordisk: Product Portfolio for Type 2 Diabetes Treatment
Table 209 : Novo Nordisk: Key Financials, 2021
Table 210 : Novo Nordisk: Selected Key Developments, 2023
Table 211 : Roche: Financials, 2021
Table 212 : Roche: Revenue, by Business Segment, 2016-2021
Table 213 : Roche: Revenue, by Diagnostic Segment, 2016-2021
Table 214 : Roche: Product Portfolio
Table 215 : Roche: Diagnostics Patient Monitoring Product Portfolio
Table 216 : Roche: Recent Developments, 2023
Table 217 : Sanofi: Product Portfolio for Type 2 Diabetes Treatment
Table 218 : Sanofi: Business Segment
Table 219 : Sanofi: Financial Performance, 2021 and 2022
Table 220 : Sanofi: Key Developments, 2023
Table 221 : Takeda: Key Financials, 2021
Table 222 : Terumo Corp.: Financials, 2021
Table 223 : Terumo Corp.: Recent Developments, 2020
Table 224 : Government Regulatory Agencies and Professional Organizations

List of Figures

Summary Figure : Global Market for Diabetes Therapeutics and Diagnostics, by Segment, 2020-2028
Figure 1 : Global Diabetes Incidence
Figure 2 : Classification of Injectable Therapies for Diabetes
Figure 3 : Classification of Oral Antidiabetic Drugs (OADs)
Figure 4 : Global Initiatives Pertaining to Type 2 Diabetes
Figure 5 : Type 2 Diabetes Agents in Clinical Development
Figure 6 : Clinical Development Pipeline for Hanmi Pharma Co. Ltd.
Figure 7 : Administration Route for Insulin Delivery
Figure 8 : Schematic of a Closed-Loop Artificial Pancreas System
Figure 9 : Schematic of the Edmonton Protocol
Figure 10 : Product Pipeline Portfolio of Diabetology Ltd.
Figure 11 : Global Market for Diabetes Therapeutics and Diagnostics, by Region
Figure 12 : Global Market Shares of Diabetes Therapeutic and Diagnostics, by Region, 2022
Figure 13 : Key Components of the German Statutory Health Insurance System, 2019
Figure 14 : Risk of Developing Diabetes-Related Comorbidities
Figure 15 : Global Market for Diabetes Therapeutics and Diagnostics Deal Activity, by Type, January 2018 to June 2023
Figure 16 : Global Market for Diabetes Therapeutics and Diagnostics Deal Activity, by Top 10 Industries, January 2018 to June 2023
Figure 17 : Global Market Share Analysis for Diabetes Therapeutics and Diagnostics, 2022
Figure 18 : Global Market Share Analysis for Diabetes Therapeutics, 2022
Figure 19 : Global Market Share Analysis for Diabetes Monitoring Devices and Accessories, 2022
Figure 20 : Global Market Share Analysis for Diabetes Delivery Devices, 2022
Figure 21 : Abbott: Revenue Share, by Country/Region, 2021 and 2022
Figure 22 : Abbott: Revenue Share, by Business Segment, 2021 and 2022
Figure 23 : Abbott: R&D Expenditures, 2015-2022
Figure 24 : AstraZeneca: Sales Share, by Segment, 2022
Figure 25 : AstraZeneca: Revenue Share, by Region, 2022
Figure 26 : Braun: Revenue, 2015-2021
Figure 27 : Braun: Revenue Share, by Country/Region, 2021
Figure 28 : Braun: Revenue Share, by Segment, 2021
Figure 29 : Boehringer Ingelheim: Annual Revenue, 2021 and 2022
Figure 30 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2021 and 2022
Figure 31 : Boehringer Ingelheim: Revenue Share, by Region, 2021 and 2022
Figure 32 : Danaher Corp.: Revenue Share, by Segment, 2021
Figure 33 : Danaher Corp.: Revenue Share, by Country/Region, 2021
Figure 34 : Dexcom Inc.: Annual Revenue, 2019-2021
Figure 35 : Dexcom: Revenue Share, by Region, 2022
Figure 36 : Dexcom: Revenue Share, by Sales Channel, 2022
Figure 37 : Johnson & Johnson: Financials, 2017-2021
Figure 38 : Johnson & Johnson: Revenue Share, by Country/Region, 2021
Figure 39 : Johnson & Johnson: Revenue Share, by Segment, 2021
Figure 40 : Lilly: Total Sales Share, by Product Segment, 2020
Figure 41 : Lilly: Revenue Share, by Product, 2020
Figure 42 : Medtronic: Financials, 2015-2022
Figure 43 : Medtronic: Revenue Share, by Country/Region, 2022
Figure 44 : Medtronic: Revenue Share, by Key Disease Segment, 2022
Figure 45 : Menarini Group: Revenue Share, by Business Segment, 2021
Figure 46 : Menarini Group: Total Revenue Share, by Region, 2021
Figure 47 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2022
Figure 48 : Merck & Co. Inc.: Revenue Share, by Region, 2022
Figure 49 : Merck KGaA: Revenue Share, by Business Segment, 2021
Figure 50 : Merck KGaA: Total Revenue Share, by Region, 2021
Figure 51 : Nipro Group: Revenue Share, by Country/Region, 2021
Figure 52 : Nipro Group: Revenue Share, by Business Segment, 2021
Figure 53 : Novartis: Revenue Share, by Business Segment, 2021
Figure 54 : Novartis: Total Revenue Share, by Region, 2021
Figure 55 : Novo Nordisk: Revenue Share, by Region, 2021
Figure 56 : Novo Nordisk: Revenue Share, by Business Segment, 2021
Figure 57 : Roche: Revenue Share, by Business Segment, 2021
Figure 58 : Roche: Revenue Share, by Country/Region, 2021
Figure 59 : Sanofi: Net Sales Share, by Business Segment, 2022
Figure 60 : Sanofi: Net Sales Share, by Region, 2022
Figure 61 : Takeda: Revenue Share, by Business Segment, 2021
Figure 62 : Takeda Pharmaceutical: Total Revenue Share, by Region, 2021
Figure 63 : Terumo Corp.: Revenue Share, by Segment, 2021
Figure 64 : Terumo Corp.: Revenue Share, by Country/Region, 2021